Literature DB >> 9517784

Single photon emission computed tomography scanning in childhood systemic lupus erythematosus.

R Russo1, D Gilday, R M Laxer, A Eddy, E D Silverman.   

Abstract

OBJECTIVE: To determine the role of central nervous system (CNS) perfusion scanning in detecting CNS disease in childhood onset systemic lupus erythematosus (SLE) and serial single photon emission computed tomography (SPECT) scans in monitoring CNS disease activity in childhood.
METHODS: The charts of 108 patients with a confirmed or suspected diagnosis of SLE during the period February 1987 to June 1992 were reviewed. Twenty patients with a diagnosis of CNS SLE and 10 patients without CNS involvement had at least one SPECT scan. Patients were divided into (a) focal CNS SLE, when there were clinical manifestations that could be attributed to localized lesions of the CNS (6 patients); and (b) diffuse CNS SLE, when there was a global defect in CNS function including organic brain syndrome, psychosis, and depression (14 patients). If a patient had both diffuse and focal CNS disease that patient was designated as having diffuse disease. Forty-three patients with a diagnosis other than SLE comprised our non-SLE control group.
RESULTS: SPECT scans were performed in 20 patients with acute CNS involvement. In patients with acute diffuse CNS disease, diffuse patchy areas of hypoperfusion were seen in 86% of patients at presentation of the CNS event. In the focal CNS disease subgroup, 33% of patients had an abnormal scan at CNS presentation. In these patients focal rather than diffuse abnormalities were seen. Eight patients with diffuse CNS SLE had at least one followup study at intervals ranging from 1 month to 3 years after initial scan. In 50% of these patients with diffuse CNS involvement, improvement in their abnormal scan correlated with clinical improvement, while in the other 50% clinical improvement was not associated with SPECT scan improvement. The most common abnormal SPECT scan pattern in patients with CNS SLE was one of widespread multiple small areas of decreased uptake at multiple sites, suggestive of generalized patchy hypoperfusion. Although SPECT scans were sensitive to the presence of CNS disease, the diffuse hypoperfusion was not specific for clinically detectable CNS involvement. In patients with SLE, a diffusely abnormal scan had a specificity of 69% and a likelihood ratio of 2.2 to correctly detect overt diffuse CNS disease.
CONCLUSION: Although we found that SPECT scanning was a highly sensitive method, it was not a specific method in correctly diagnosing diffuse CNS SLE in children. However, the presence of an abnormal SPECT scan in SLE patients with no history of overt CNS SLE may suggest that subclinical CNS disease may be more common in children than previously suggested.

Entities:  

Mesh:

Year:  1998        PMID: 9517784

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

2.  Elevated cerebral blood flow and volume in systemic lupus measured by dynamic susceptibility contrast magnetic resonance imaging.

Authors:  Charles M Gasparovic; Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Paul G Mullins; Janeen M Sharrar; J Jeremy Yamamoto; H Jeremy Bockholt
Journal:  J Rheumatol       Date:  2010-06-15       Impact factor: 4.666

3.  Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping.

Authors:  Mari Miyata; Shingo Kakeda; Kohsuke Kudo; Shigeru Iwata; Yoshiya Tanaka; Yi Wang; Yukunori Korogi
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-16       Impact factor: 6.200

4.  Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus.

Authors:  Mohamed O Olfat; Sulaiman M Al-Mayouf; Mohamed A Muzaffer
Journal:  Clin Rheumatol       Date:  2004-07-23       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.